[
  {
    "question": "trident sign on MRI spine , with case of RRMS not improving despite being on DMT, Dx?",
    "option_a": "Sarcoidosis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The 'trident sign' on MRI spine is a well\u2010recognized radiological finding associated with neurosarcoidosis. In cases of relapsing\u2010remitting MS that do not respond to disease\u2010modifying therapy (DMT), it is important to reconsider the diagnosis. Neurosarcoidosis can mimic MS, and the \u2018trident sign\u2019 (characterized by a central linear enhancement with dorsal subpial involvement) is a clue to this alternative diagnosis. Neurosarcoidosis is due to granulomatous inflammation with non-caseating granulomas that can affect any part of the central nervous system. In the spinal cord, an inflammatory process along the perivascular spaces produces a pattern of dorsal subpial and central enhancement, resulting in the so\u2010called trident appearance on MRI. Clinically, neurosarcoidosis may present with multifocal neurological deficits that mimic MS. In a patient diagnosed with RRMS who fails to improve on DMT, the presence of atypical imaging findings (such as the trident sign) should prompt reconsideration of the diagnosis. Additional systemic signs of sarcoidosis (e.g., pulmonary involvement, uveitis) may be present. The differential diagnosis includes MS, neuromyelitis optica spectrum disorder, infectious myelitis, and spinal cord neoplasms. Workup should include CSF analysis, serum angiotensin converting enzyme (ACE) levels, chest imaging (CT), and sometimes tissue biopsy to confirm non-caseating granulomas. First-line therapy for neurosarcoidosis involves high-dose corticosteroids followed by a slow taper. If patients are refractory to steroids, second-line agents such as methotrexate, azathioprine, or TNF-alpha inhibitors (e.g., infliximab) may be considered. In pregnancy, corticosteroids remain the mainstay after a careful risk/benefit discussion, and many immunosuppressants carry pregnancy risk and require multidisciplinary management. During lactation, agents with low transfer into breast milk are preferred. Option A (Sarcoidosis) is correct because the trident sign on spinal MRI is highly suggestive of neurosarcoidosis, which can mimic MS especially when standard DMTs fail to yield improvement. Other options were not provided, but by integrating the clues from imaging and clinical non-response to DMT, sarcoidosis is the most likely alternative diagnosis. 1. The trident sign is a critical clue to neurosarcoidosis in patients initially thought to have MS. 2. A lack of response to MS DMTs should prompt reevaluation of the diagnosis. 3. Systematic evaluation for systemic sarcoidosis (such as a chest CT) is recommended in atypical cases. Recent studies emphasize the role of advanced MRI techniques to identify unusual enhancement patterns seen in neurosarcoidosis. Updated guidelines recommend that patients with atypical MS presentations be evaluated for sarcoidosis with systemic imaging and possibly biopsy, ensuring that treatment is appropriately targeted.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Which DMT causes ITP (picture of purpura)?",
    "option_a": "(Sarcoidosis) is correct because the trident sign on spinal MRI is highly suggestive of neurosarcoidosis, which can mimic MS especially when standard DMTs fail to yield improvement. Other options were not provided, but by integrating the clues from imaging and clinical non",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The 'trident sign' on MRI spine is a well\u2010recognized radiological finding associated with neurosarcoidosis. In cases of relapsing\u2010remitting MS that do not respond to disease\u2010modifying therapy (DMT), it is important to reconsider the diagnosis. Neurosarcoidosis can mimic MS, and the \u2018trident sign\u2019 (characterized by a central linear enhancement with dorsal subpial involvement) is a clue to this alternative diagnosis. Neurosarcoidosis is due to granulomatous inflammation with non-caseating granulomas that can affect any part of the central nervous system. In the spinal cord, an inflammatory process along the perivascular spaces produces a pattern of dorsal subpial and central enhancement, resulting in the so\u2010called trident appearance on MRI. Clinically, neurosarcoidosis may present with multifocal neurological deficits that mimic MS. In a patient diagnosed with RRMS who fails to improve on DMT, the presence of atypical imaging findings (such as the trident sign) should prompt reconsideration of the diagnosis. Additional systemic signs of sarcoidosis (e.g., pulmonary involvement, uveitis) may be present. The differential diagnosis includes MS, neuromyelitis optica spectrum disorder, infectious myelitis, and spinal cord neoplasms. Workup should include CSF analysis, serum angiotensin converting enzyme (ACE) levels, chest imaging (CT), and sometimes tissue biopsy to confirm non-caseating granulomas. First-line therapy for neurosarcoidosis involves high-dose corticosteroids followed by a slow taper. If patients are refractory to steroids, second-line agents such as methotrexate, azathioprine, or TNF-alpha inhibitors (e.g., infliximab) may be considered. In pregnancy, corticosteroids remain the mainstay after a careful risk/benefit discussion, and many immunosuppressants carry pregnancy risk and require multidisciplinary management. During lactation, agents with low transfer into breast milk are preferred. Option A (Sarcoidosis) is correct because the trident sign on spinal MRI is highly suggestive of neurosarcoidosis, which can mimic MS especially when standard DMTs fail to yield improvement. Other options were not provided, but by integrating the clues from imaging and clinical non-response to DMT, sarcoidosis is the most likely alternative diagnosis. 1. The trident sign is a critical clue to neurosarcoidosis in patients initially thought to have MS. 2. A lack of response to MS DMTs should prompt reevaluation of the diagnosis. 3. Systematic evaluation for systemic sarcoidosis (such as a chest CT) is recommended in atypical cases. Recent studies emphasize the role of advanced MRI techniques to identify unusual enhancement patterns seen in neurosarcoidosis. Updated guidelines recommend that patients with atypical MS presentations be evaluated for sarcoidosis with systemic imaging and possibly biopsy, ensuring that treatment is appropriately targeted.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient known to have MS but has psoriasis what DMT to give?",
    "option_a": "(Sarcoidosis) is correct because the trident sign on spinal MRI is highly suggestive of neurosarcoidosis, which can mimic MS especially when standard DMTs fail to yield improvement. Other options were not provided, but by integrating the clues from imaging and clinical non",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The 'trident sign' on MRI spine is a well\u2010recognized radiological finding associated with neurosarcoidosis. In cases of relapsing\u2010remitting MS that do not respond to disease\u2010modifying therapy (DMT), it is important to reconsider the diagnosis. Neurosarcoidosis can mimic MS, and the \u2018trident sign\u2019 (characterized by a central linear enhancement with dorsal subpial involvement) is a clue to this alternative diagnosis. Neurosarcoidosis is due to granulomatous inflammation with non-caseating granulomas that can affect any part of the central nervous system. In the spinal cord, an inflammatory process along the perivascular spaces produces a pattern of dorsal subpial and central enhancement, resulting in the so\u2010called trident appearance on MRI. Clinically, neurosarcoidosis may present with multifocal neurological deficits that mimic MS. In a patient diagnosed with RRMS who fails to improve on DMT, the presence of atypical imaging findings (such as the trident sign) should prompt reconsideration of the diagnosis. Additional systemic signs of sarcoidosis (e.g., pulmonary involvement, uveitis) may be present. The differential diagnosis includes MS, neuromyelitis optica spectrum disorder, infectious myelitis, and spinal cord neoplasms. Workup should include CSF analysis, serum angiotensin converting enzyme (ACE) levels, chest imaging (CT), and sometimes tissue biopsy to confirm non-caseating granulomas. First-line therapy for neurosarcoidosis involves high-dose corticosteroids followed by a slow taper. If patients are refractory to steroids, second-line agents such as methotrexate, azathioprine, or TNF-alpha inhibitors (e.g., infliximab) may be considered. In pregnancy, corticosteroids remain the mainstay after a careful risk/benefit discussion, and many immunosuppressants carry pregnancy risk and require multidisciplinary management. During lactation, agents with low transfer into breast milk are preferred. Option A (Sarcoidosis) is correct because the trident sign on spinal MRI is highly suggestive of neurosarcoidosis, which can mimic MS especially when standard DMTs fail to yield improvement. Other options were not provided, but by integrating the clues from imaging and clinical non-response to DMT, sarcoidosis is the most likely alternative diagnosis. 1. The trident sign is a critical clue to neurosarcoidosis in patients initially thought to have MS. 2. A lack of response to MS DMTs should prompt reevaluation of the diagnosis. 3. Systematic evaluation for systemic sarcoidosis (such as a chest CT) is recommended in atypical cases. Recent studies emphasize the role of advanced MRI techniques to identify unusual enhancement patterns seen in neurosarcoidosis. Updated guidelines recommend that patients with atypical MS presentations be evaluated for sarcoidosis with systemic imaging and possibly biopsy, ensuring that treatment is appropriately targeted.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "24 year old female, developed abrupt vision loss (did not mention painful or painless) in left eye then affected the right eye after two to three days and was static thereafter. Fundoscopy showed pale optic discs, next immediate step?",
    "option_a": "no treatment needed",
    "option_b": "pulse steroids",
    "option_c": "plex",
    "option_d": "IVIG",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The 'trident sign' on MRI spine is a well\u2010recognized radiological finding associated with neurosarcoidosis. In cases of relapsing\u2010remitting MS that do not respond to disease\u2010modifying therapy (DMT), it is important to reconsider the diagnosis. Neurosarcoidosis can mimic MS, and the \u2018trident sign\u2019 (characterized by a central linear enhancement with dorsal subpial involvement) is a clue to this alternative diagnosis. Neurosarcoidosis is due to granulomatous inflammation with non-caseating granulomas that can affect any part of the central nervous system. In the spinal cord, an inflammatory process along the perivascular spaces produces a pattern of dorsal subpial and central enhancement, resulting in the so\u2010called trident appearance on MRI. Clinically, neurosarcoidosis may present with multifocal neurological deficits that mimic MS. In a patient diagnosed with RRMS who fails to improve on DMT, the presence of atypical imaging findings (such as the trident sign) should prompt reconsideration of the diagnosis. Additional systemic signs of sarcoidosis (e.g., pulmonary involvement, uveitis) may be present. The differential diagnosis includes MS, neuromyelitis optica spectrum disorder, infectious myelitis, and spinal cord neoplasms. Workup should include CSF analysis, serum angiotensin converting enzyme (ACE) levels, chest imaging (CT), and sometimes tissue biopsy to confirm non-caseating granulomas. First-line therapy for neurosarcoidosis involves high-dose corticosteroids followed by a slow taper. If patients are refractory to steroids, second-line agents such as methotrexate, azathioprine, or TNF-alpha inhibitors (e.g., infliximab) may be considered. In pregnancy, corticosteroids remain the mainstay after a careful risk/benefit discussion, and many immunosuppressants carry pregnancy risk and require multidisciplinary management. During lactation, agents with low transfer into breast milk are preferred. Option A (Sarcoidosis) is correct because the trident sign on spinal MRI is highly suggestive of neurosarcoidosis, which can mimic MS especially when standard DMTs fail to yield improvement. Other options were not provided, but by integrating the clues from imaging and clinical non-response to DMT, sarcoidosis is the most likely alternative diagnosis. 1. The trident sign is a critical clue to neurosarcoidosis in patients initially thought to have MS. 2. A lack of response to MS DMTs should prompt reevaluation of the diagnosis. 3. Systematic evaluation for systemic sarcoidosis (such as a chest CT) is recommended in atypical cases. Recent studies emphasize the role of advanced MRI techniques to identify unusual enhancement patterns seen in neurosarcoidosis. Updated guidelines recommend that patients with atypical MS presentations be evaluated for sarcoidosis with systemic imaging and possibly biopsy, ensuring that treatment is appropriately targeted.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young female, with RRMS, has previous TM, was on Fingolomod then she stopped fingolomod and got pregnant, she had worsening of her weakness and noticed change in urine smell, most likely she has?",
    "option_a": "rebound disease",
    "option_b": "pseudo relapse",
    "option_c": "true relapse",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "In multiple sclerosis (MS), a relapse can be classified as a true relapse (new inflammatory demyelinating activity), pseudo-relapse (transient worsening due to external factors like infection or heat), or rebound disease (severe disease activity after stopping a potent disease\u2010modifying therapy, such as fingolimod). Recognizing the trigger is essential in differentiating these phenomena. A pseudo-relapse is caused by temporary factors that worsen preexisting neurological deficits without new demyelination. In this case, the change in urine smell is a red flag for a urinary tract infection (UTI), which can precipitate transient symptom worsening. Although discontinuation of fingolimod can lead to rebound inflammatory activity, the presence of a likely infection points toward a pseudo-relapse rather than new inflammatory lesions. In patients with relapsing\u2013remitting MS, infections such as UTIs can exacerbate preexisting deficits, resulting in a pseudo-relapse. The fact that this young female patient, who stopped fingolimod due to pregnancy, exhibits a change in urine odor (suggestive of UTI) makes pseudo-relapse the most likely scenario. Rebound disease typically presents without an infectious trigger and is characterized by severe, often multifocal, neurological deterioration. The initial diagnostic evaluation should include a careful history and physical exam, with laboratory assessment including urinalysis and urine culture to confirm UTI. If there is any suspicion of a true relapse, magnetic resonance imaging (MRI) with contrast should be obtained to detect new active lesions. Differential diagnoses include a true relapse (new inflammatory lesions), a pseudo-relapse due to infection or heat, and rebound disease following DMT discontinuation. Management of a pseudo-relapse involves treating the underlying trigger\u2014in this case, a UTI\u2014with appropriate antibiotics (considering pregnancy\u2010safe options such as nitrofurantoin when indicated). It is important to avoid unnecessary escalation of immunosuppression. In cases of true relapse or rebound, high-dose corticosteroids or other additional immunotherapy might be indicated. In pregnant patients, antibiotic choices should be selected based on safety in pregnancy and, if lactating, based on their compatibility with breastfeeding. Option A (rebound disease) is typically considered when severe disease activity emerges after stopping fingolimod without an obvious external trigger; however, the presence of UTI signs makes it unlikely. Option B (pseudo relapse) is correct because the patient\u2019s worsening symptoms are most consistent with a transient exacerbation due to UTI. Option C (true relapse) would require new inflammatory activity, usually confirmed by imaging, and is less likely when an infection is present. 1) UTIs are a common trigger for pseudo-relapse in MS patients. 2) Fingolimod discontinuation can lead to rebound disease, so clinical clues (like infection signs) are crucial for differentiation. 3) Always rule out infections before treating presumed MS relapses. Current guidelines emphasize evaluating for infections such as UTIs when MS patients present with worsening symptoms, particularly in the context of DMT changes. Recent research and consensus recommend that clinicians distinguish pseudo-relapses from true relapses using clinical assessment and targeted investigations, ensuring that treatment is appropriately directed.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient was diagnosed with Multiple sclerosis and has Psoriasis, what is an appropriate DMT for her case?",
    "option_a": "Dimethyl fumarate",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Choosing an appropriate disease\u2010modifying therapy (DMT) in MS requires taking into account the patient\u2019s comorbid conditions. Dimethyl fumarate is approved for relapsing\u2013remitting MS and, given its mechanism and use in a formulation for psoriasis (fumaric acid esters have been long used in dermatology), it becomes a favored option in patients with both MS and psoriasis. Dimethyl fumarate (DMF) exerts its therapeutic effects by activating the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to anti-inflammatory and neuroprotective effects. Its immunomodulatory action helps reduce the frequency of MS relapses while also modulating inflammatory pathways involved in psoriasis. For patients with both MS and psoriasis, DMF offers the dual advantage of managing central nervous system autoimmune demyelination and potentially ameliorating skin inflammation. This dual action makes DMF a particularly attractive choice when comorbid autoimmune conditions are present. When determining the most appropriate DMT for an MS patient with psoriasis, clinicians should review the patient\u2019s overall disease profile, severity, and comorbid conditions. Differential considerations include other DMTs like interferons, glatiramer acetate, or newer agents, but none have the added benefit for psoriasis that DMF offers. Dimethyl fumarate is considered a first\u2010line therapy for relapsing\u2013remitting MS. Treatment regimens should be individualized based on severity and patient comorbidities. In women of childbearing potential, including those who are pregnant or lactating, current guidelines recommend careful risk\u2013benefit analysis. Although human data on DMF in pregnancy are limited, decisions should be made in a multidisciplinary setting, and if treatment is initiated, patients should be counseled on potential risks and monitored closely. Option A (Dimethyl fumarate) is correct since it effectively manages MS while also offering benefits for psoriasis. Other options (not provided) may lack the advantage of dual benefit or have less favorable safety profiles in the setting of comorbid autoimmune skin disease. 1) DMF is unique among MS DMTs for its potential beneficial effects on psoriasis. 2) Comorbid autoimmune conditions can guide the choice of DMT to maximize overall patient benefit. 3) Always consider reproductive plans when selecting a DMT due to potential pregnancy and lactation concerns. Recent research supports the use of DMF in relapsing\u2013remitting MS, with evidence of efficacy and manageable safety profiles. Its established role in psoriasis in certain regions further supports its use in patients with both conditions, with ongoing studies aimed at better elucidating its long-term effects in special populations.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Which DMT causes ITP? (attached picture of purpura)",
    "option_a": "Alemtuzumab",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The identification of drug-induced immune-mediated complications is critical in MS management. Alemtuzumab is a potent monoclonal antibody that targets CD52 on lymphocytes, resulting in profound immune depletion. A key adverse event associated with alemtuzumab is the development of secondary autoimmunity, including immune thrombocytopenic purpura (ITP). Alemtuzumab causes rapid lymphocyte depletion which can lead to an imbalance in regulatory and autoreactive immune cells. This immune reconstitution may trigger autoimmunity, including ITP, where the immune system erroneously targets platelets for destruction, resulting in thrombocytopenia and associated bleeding manifestations. Patients receiving alemtuzumab require close monitoring for signs of ITP, including petechiae, purpura, and bleeding tendencies. The appearance of skin lesions such as purpura (as depicted in the attached image) should prompt immediate evaluation of platelet counts. When ITP is suspected, a complete blood count (CBC) and peripheral smear are essential to confirm thrombocytopenia. Differential diagnoses include other causes of low platelets such as drug-induced thrombocytopenia (from other medications), disseminated intravascular coagulation, or viral infections. Regular monthly monitoring of blood counts is mandated in patients treated with alemtuzumab. Management of alemtuzumab-associated ITP involves early detection through regular monitoring of CBCs and prompt treatment with corticosteroids or intravenous immunoglobulin (IVIG) as necessary. In the setting of pregnancy or lactation, management of ITP requires careful antibiotic and immunosuppressant selection; steroids can be used at the lowest effective dose with obstetrical collaboration to ensure safety for both mother and fetus. Option A (Alemtuzumab) is correct because it is the MS DMT that is most notably associated with ITP among the available agents. Other DMTs have different side effect profiles and are not commonly linked to immune-mediated thrombocytopenia. 1) Alemtuzumab is associated with a significant risk of secondary autoimmunity, including ITP. 2) Regular monthly monitoring of blood counts post-treatment is essential for early detection of ITP. 3) Early management of ITP can prevent serious hemorrhagic complications. Recent guideline updates and post-marketing surveillance data have reinforced the need for vigilant monitoring following alemtuzumab treatment. Research continues to elucidate the mechanisms behind its autoimmune complications, leading to refined monitoring protocols and early intervention strategies.",
    "exam_year": "2024",
    "exam_type": "Part II",
    "image_url": "page_12.png"
  },
  {
    "question": "Patient was diagnosed with multiple sclerosis, what would be a favorable factor in her case?",
    "option_a": "Brainstem onset",
    "option_b": "Male gender",
    "option_c": "Young age of onset",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis prognosis is influenced by several factors. Favorable prognostic factors include a relapsing\u2013remitting course, female gender, and younger age at onset. A younger age at onset often correlates with a longer time taken to accumulate significant disability, despite the possibility of more frequent relapses. In younger patients, the central nervous system exhibits a higher capacity for repair and remyelination. This neuroplasticity and potential for compensatory mechanisms can result in a slower progression of disability over time compared to those with an older onset. Although younger patients may experience relapses more frequently, they tend to recover better and accrue disability at a slower pace. Conversely, brainstem involvement or male gender have generally been associated with a less favorable prognosis, as these factors are linked to increased disability accumulation and a more aggressive disease course. Prognostication in MS involves assessing the site of onset (e.g., optic neuritis versus brainstem or motor involvement), age at onset, gender, and other clinical markers. Differential prognostic indicators include the pattern of relapses versus progressive onset and the specific neurological functions affected. Early initiation of DMTs is recommended for all patients with MS. In patients with a favorable prognostic factor such as young age of onset, early aggressive therapy might help prolong the period of minimal disability. For women who are pregnant or considering pregnancy, treatment decisions should involve a careful risk\u2013benefit analysis given that many DMTs have limited data in pregnancy and lactation; some agents are contraindicated while others may be used with caution. Option A (Brainstem onset) is generally unfavorable because it is associated with more severe disability. Option B (Male gender) is also considered less favorable due to a typically more aggressive disease course in males. Option C (Young age of onset) is correct as it is associated with a slower accrual of disability over time, despite more frequent relapses. 1) Younger age at onset in MS is linked with a more benign long-term course despite high relapse frequency. 2) Brainstem involvement often portends a worse prognosis due to more critical functional deficits. 3) Prognostic evaluation is essential for guiding early treatment decisions. The latest research and clinical guidelines continue to support that early age of onset is a favorable prognostic indicator in MS. Ongoing studies are focused on better understanding the interplay between age, neuroplasticity, and the disease-modifying effects of early treatment interventions.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient was diagnosed with Multiple sclerosis for 8 months, based on initial attack was transverse myelitis caused lower limbs symptoms, now she pregnant and off DMT. She presented with lower limb numbness and reported a change in her urine smell and odor, what is the diagnosis?",
    "option_a": "MS pseudorelapse",
    "option_b": "MS relapse",
    "option_c": "MS rebound activity",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "In multiple sclerosis (MS), a pseudorelapse is defined as a temporary worsening of pre\u2010existing neurological symptoms not caused by new inflammatory demyelinating activity but rather by external factors such as infections, heat, or other systemic stressors. In this case, the patient\u2019s new lower limb numbness in the setting of a urinary change (altered urine odor suggestive of a urinary tract infection) is indicative of a pseudorelapse. In MS, demyelinated nerve fibers have decreased conduction efficiency. External factors like infections (eg, UTI) can lead to an increase in inflammatory cytokines and a transient disruption of nerve conduction (often termed a conduction block) without the formation of new lesions. This mechanism underlies a pseudorelapse, differentiating it from a true relapse where new inflammatory lesions are present. The patient, who is 8 months into her MS diagnosis and has been off disease\u2010modifying therapy (DMT) during pregnancy, presents with lower limb numbness and a change in urine odor. Infections, particularly UTIs, are common during pregnancy and can transiently worsen neurological symptoms in MS patients. This presentation is clinically consistent with a pseudorelapse rather than a new inflammatory event. The evaluation involves differentiating a pseudorelapse from a true relapse. This typically includes a thorough clinical history and examination, urine analysis and culture (to confirm UTI), and, if needed, MRI imaging to assess for new lesions. A true relapse would be characterized by new or enlarging lesions on MRI along with objective clinical findings, while pseudorelapse is often reversible with treatment of the underlying cause. The management of a pseudorelapse centers on treating the underlying cause (in this case, a UTI). Guidelines suggest using antibiotics that are safe for use during pregnancy (eg, nitrofurantoin, ampicillin, or cephalosporins, while considering gestational age and local resistance patterns). There is no need to escalate or change MS-specific DMT. Additionally, symptomatic treatment for any discomfort may be provided while monitoring improvement. Option A (MS pseudorelapse) is correct because the new symptoms are most likely triggered by an infection (UTI indicated by the abnormal urine odor) rather than by new inflammatory demyelination. Option B (MS relapse) would require evidence of new lesion formation and sustained inflammatory activity, and Option C (MS rebound activity) is typically seen after cessation of highly effective DMTs like natalizumab, not in this context. 1. Transient worsening of MS symptoms in the context of an infection is common and termed a pseudorelapse. 2. Always evaluate for infections (eg, UTI in pregnant patients) before diagnosing a true relapse, as management differs significantly. Recent guidelines emphasize the need to rule out pseudorelapses by addressing triggers such as infections before initiating high-dose steroids for presumed relapses. Contemporary research supports close monitoring of pregnant MS patients, given their increased susceptibility to infections that may mimic relapse symptoms.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Which of the following considered red flag for Multiple Sclerosis (or demyelinating disease)?",
    "option_a": "Persistent enhancement for 3 months",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "In evaluating demyelinating diseases like MS, certain radiologic findings are considered red flags that should prompt reconsideration of the diagnosis. One such red flag is the persistence of lesion enhancement on MRI for an unusually long period. Active MS lesions typically exhibit contrast enhancement for a limited period (usually 3\u20106 weeks) reflecting transient blood\u2013brain barrier breakdown. Persistent enhancement for as long as 3 months is atypical and may indicate alternative pathologies such as neoplastic processes, infections, or inflammatory conditions like neurosarcoidosis. When lesions on MRI continue to show contrast enhancement beyond the expected timeframe, it raises concern for conditions other than classic MS. This abnormal prolonged enhancement guides clinicians to look for alternative etiologies and re-evaluate the diagnosis. The differential diagnosis for persistent enhancement includes neoplastic lesions, neurosarcoidosis, chronic active demyelination, and other inflammatory processes. Clinicians should correlate imaging findings with clinical presentation, laboratory studies, and, if necessary, consider biopsy or further advanced imaging techniques to distinguish these conditions. When a red flag is identified, further diagnostic testing is warranted to rule out alternative causes. This may include advanced imaging (eg, MR spectroscopy), laboratory panels (eg, markers for vasculitis, sarcoidosis, or infection), and sometimes biopsy. Management then pivots to the specific diagnosed condition. For patients who are pregnant or lactating, careful evaluation must be conducted with imaging modalities that minimize fetal exposure (eg, using MRI without contrast when possible) and avoiding potentially teratogenic diagnostic procedures. Option A (Persistent enhancement for 3 months) is a red flag because it is not consistent with the typical transient enhancement seen in MS lesions. The other options (which were not specified) likely do not represent this critical atypical feature. 1. In MS, active lesions normally enhance for only a few weeks; persistence beyond 2 months should prompt reconsideration of the diagnosis. 2. Always integrate clinical and radiologic data to differentiate MS from its mimics. The latest updates in the McDonald criteria emphasize the temporal pattern of lesion enhancement. Recent studies suggest that persistent enhancement is more frequently associated with alternative diagnoses rather than with MS, thereby influencing both the diagnostic workup and subsequent management strategies.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "What DMT has 30% increased risk of secondary autoimmune disorders?",
    "option_a": "Alemtuzumab",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Disease-modifying therapies (DMTs) for MS are designed to modulate or suppress the immune system. Some of these therapies carry a risk of inducing secondary autoimmune disorders as a side effect. Alemtuzumab, in particular, is well-known for this risk. Alemtuzumab is a monoclonal antibody that targets CD52 on mature lymphocytes, leading to profound lymphocyte depletion. During the repopulation phase, immune dysregulation can occur, predisposing patients to secondary autoimmune conditions, most commonly thyroid disorders, but also immune thrombocytopenia and other autoimmune manifestations. The reported incidence is around 30%, making it a notable adverse effect. Patients treated with alemtuzumab are at increased risk for developing autoimmune thyroid disease and other secondary autoimmune conditions. This risk necessitates careful patient selection and close long-term monitoring post-treatment. Monitoring includes regular thyroid function tests (eg, TSH, free T4) and other autoimmune markers periodically for several years post-treatment. Clinicians should remain vigilant for clinical signs and symptoms suggestive of autoimmunity and respond promptly with the appropriate investigations. Guidelines recommend that patients receiving alemtuzumab undergo baseline assessment and then periodic screening (often every 3 months) for autoimmune thyroid disease and other secondary autoimmune conditions for at least 48 months post-treatment. In women who are pregnant or planning pregnancy, the risks of alemtuzumab must be carefully weighed against the benefits; women are generally advised to use effective contraception during treatment and for a specified period afterward. During lactation, the decision to continue or withhold alemtuzumab should involve a thorough risk-benefit discussion, as data in this population are limited. Option A (Alemtuzumab) is correct because it is the DMT most associated with a roughly 30% increased risk of secondary autoimmune disorders. Other DMTs do not share this same high risk profile. 1. Autoimmune thyroid disease is the most common secondary autoimmune complication seen with alemtuzumab therapy, occurring in approximately 30% of treated patients. 2. Long-term monitoring for autoimmunity is essential in patients receiving alemtuzumab. Recent post-marketing surveillance and clinical studies continue to confirm the high incidence of secondary autoimmune events with alemtuzumab. Updated guidelines stress the importance of routine monitoring and patient education regarding the signs and symptoms of autoimmunity.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient known case of NMO after long cervical myelitis, reported that she has pain over her upper limbs triggered by sudden movement. What is the best treatment?",
    "option_a": "Carbamazepine",
    "option_b": "Gabapentin",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Patients with neuromyelitis optica (NMO) often experience complications related to extensive demyelinating episodes. One such complication is the development of painful symptoms, such as paroxysmal dysaesthesia or painful tonic spasms, which can be triggered by sudden movements. After an episode of long cervical myelitis, as seen in NMO, neuronal hyperexcitability may occur in the damaged regions of the spinal cord. This heightened excitability can result in paroxysmal pain episodes when triggered by mechanical stimuli, such as sudden movement. Carbamazepine, a sodium channel blocker, helps stabilize hyperexcited neural membranes and reduce the frequency and intensity of these painful spasms. The patient\u2019s description of pain in her upper limbs that is triggered by sudden movement is characteristic of paroxysmal painful tonic spasms seen in demyelinating conditions. Carbamazepine is often effective in reducing or eliminating these brief, recurrent neuralgic pain episodes. The diagnosis is primarily clinical, based on the history of demyelinating disease (NMO in this case), the pattern of pain, and response to symptomatic therapy. Differential diagnoses include spasticity-related pain, peripheral neuropathy, or other forms of central neuropathic pain. A detailed neurological examination and, when necessary, electrophysiological studies can help rule out other causes. First-line treatment for paroxysmal painful tonic spasms in patients with NMO consists of sodium channel blockers such as carbamazepine, which reduce neural hyperexcitability. If patients are unable to tolerate carbamazepine or if the pain is refractory, alternatives such as oxcarbazepine or gabapentin may be considered. In the context of pregnancy and lactation, carbamazepine is classified as having teratogenic potential (notably neural tube defects), so women of childbearing age require adequate folic acid supplementation and close obstetric consultation before and during treatment. The risks and benefits must be carefully weighed, and alternative agents with a safer pregnancy profile may need to be considered where appropriate. Option A (Carbamazepine) is the best treatment for this patient given its proven efficacy in managing paroxysmal painful tonic spasms by stabilizing hyperexcitable neural membranes via sodium channel blockade. Option B (Gabapentin) is commonly used for neuropathic pain, but evidence supports carbamazepine as more effective specifically for paroxysmal dysaesthesias associated with demyelinating diseases. 1. Paroxysmal tonic spasms in demyelinating diseases such as NMO or MS are often exquisitely responsive to sodium channel blockers like carbamazepine. 2. When prescribing carbamazepine for women of childbearing potential, ensure adequate folic acid supplementation and close monitoring due to its potential teratogenic effects. Recent research and clinical guidelines continue to endorse carbamazepine as first-line therapy for paroxysmal painful tonic spasms in the context of demyelinating conditions. Ongoing studies are exploring alternative treatment strategies, but current evidence supports its use as the most effective option in these cases.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient was diagnosed with Multiple Sclerosis, suffer from lower limb tonic spasm, what is the treatment?",
    "option_a": "Carbamazepine",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system. Among its various clinical manifestations, paroxysmal symptoms\u2014such as tonic spasms\u2014are recognized phenomena. In MS, these short, episodic, involuntary contractions (often described as tonic spasms) can occur in the lower limbs. In MS, focal demyelination leads to disrupted nerve conduction and neuronal hyperexcitability. This predisposes some patients to develop episodic paroxysmal phenomena. The transient periods of abnormal conduction, possibly due to ectopic impulse generation in demyelinated nerve fibers, lead to the tonic spasms observed in these patients. Patients with MS may experience sudden, brief episodes of debilitating muscle contractions, often mistaken for seizure-like activity. It is important to distinguish these paroxysmal tonic spasms from continuous spasticity. The episodic nature, rapid onset and resolution after a few seconds to minutes, and their responsiveness to anticonvulsants help clinch their identification in the clinical setting. The diagnosis of these spasms is primarily clinical. Neuroimaging (MRI) is used to confirm the diagnosis of MS and to assess the extent and distribution of demyelinating lesions. Differential diagnoses include epileptic phenomena, primary spasticity syndromes, and other movement disorders. A careful history, examination, and correlation with imaging findings are necessary for accurate diagnosis. Carbamazepine is considered a first\u2010line treatment for paroxysmal tonic spasms in MS due to its efficacy as a sodium channel blocker. It helps reduce neuronal hyperexcitability. Although baclofen is the typical first-line agent for continuous spasticity, carbamazepine specifically targets the paroxysmal episodes. For pregnant or lactating patients, carbamazepine can be used if the benefits outweigh the risks. However, its use necessitates folic acid supplementation and careful monitoring because of its teratogenic potential and possible neonatal effects during lactation. Option A (Carbamazepine) is correct because it specifically addresses paroxysmal tonic spasms seen in some MS patients. Other agents (such as baclofen or tizanidine) might be more appropriate for chronic spasticity rather than the brief, episodic tonic spasms. 1) Paroxysmal tonic spasms in MS are brief, episodic, and respond well to anticonvulsants like carbamazepine. 2) Differentiating paroxysmal spasms from continuous spasticity is critical for selecting the appropriate treatment. Recent studies and clinical practice guidelines continue to support the use of carbamazepine for paroxysmal symptoms in MS. Although research is ongoing regarding the optimal management of MS-related spasticity, the evidence for carbamazepine\u2019s efficacy in treating paroxysmal tonic spasms remains robust.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Which of the following is suggestive of Multiple Sclerosis, but not vascular what matter disease?",
    "option_a": "Cortical involvement",
    "option_b": "Involving U fiber",
    "option_c": "Corona radiata",
    "option_d": "pons",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "MS typically features lesions in specific areas of the brain including periventricular regions, juxtacortical (U-fiber) areas, the brainstem, and the spinal cord. The involvement of U-fibers (short association fibers immediately adjacent to the cortex) is a hallmark of demyelinating disorders like MS and is rarely seen in vascular white matter disease. In MS, autoimmune-mediated demyelination targets the central nervous system in a patchy distribution. This process often involves the juxtacortical white matter (U-fibers), which is less susceptible to the vascular changes seen in small vessel ischemic disease. Vascular white matter disease usually affects deeper white matter and spares the U-fibers due to different vascular supply and susceptibility patterns. The identification of lesions involving the U-fibers on MRI is strongly suggestive of MS. Radiologically, MS lesions tend to be ovoid, periventricular, and may extend to juxtacortical regions, whereas vascular white matter disease is more diffuse and typically spares the U-fibers. When evaluating white matter lesions, the differential includes MS, vascular (ischemic) white matter disease, leukodystrophies, and other inflammatory diseases. Key factors such as patient age, risk factor profile, lesion location, shape, and distribution help differentiate these conditions. In MS, the presence of U-fiber involvement is a crucial imaging finding. Accurate imaging interpretation guides the decision to initiate disease modifying therapy (DMT) in MS. While this question focuses on radiologic features, the proper classification of lesions helps in treatment stratification. In pregnant or lactating patients, DMT selection requires careful consideration of each agent\u2019s safety profile, with some, such as interferon-beta or glatiramer acetate, having more established safety records. Option B (Involving U fiber) is correct because lesions in the U-fiber regions are typically seen in MS and are not a feature of vascular white matter disease. Option A (Cortical involvement) is less reliable because vascular disease can also affect cortical regions, while options C (Corona radiata) and D (pons) are common sites for both demyelinating and vascular lesions. 1) Juxtacortical (U-fiber) involvement is a key imaging feature that favors MS over vascular white matter disease. 2) The McDonald criteria emphasize the importance of lesion location, including U-fiber involvement, for the diagnosis of MS. The 2017 revisions of the McDonald criteria underscore the diagnostic importance of lesions in the U-fiber regions. Newer imaging techniques continue to refine how these lesions are detected and distinguished from vascular changes.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "16 years old with symptoms of optic neuritis and brain MRI attached showing bilateral extensive enhancement in optic nerve, rest of MRI is normal, what is the diagnosis? (No NMOSD in the choices)",
    "option_a": "MOGAD",
    "option_b": "ADEM",
    "option_c": "MS",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This clinical scenario describes a 16\u2010year\u2010old patient with optic neuritis and MRI findings of bilateral, extensive enhancement of the optic nerves in the absence of other brain lesions. These findings are characteristic of a condition known as MOG-associated disorder (MOGAD). MOGAD is mediated by antibodies targeting the myelin oligodendrocyte glycoprotein on the surface of oligodendrocytes, leading to demyelination. It often affects the optic nerves and spinal cord, and typically produces an inflammatory response that is more extensive (often bilateral in the optic nerves) than the unilateral involvement seen in classic MS-associated optic neuritis. Clinically, MOGAD often manifests in children and adolescents with bilateral optic neuritis. The extensive enhancement pattern on MRI supports an inflammatory etiology distinct from that seen in MS, which more commonly results in unilateral optic neuritis along with additional brain lesions. The differential diagnosis in a patient with optic neuritis includes MS, neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM). MS-associated optic neuritis is typically unilateral and is accompanied by other brain lesions. ADEM generally presents with multifocal brain lesions and encephalopathy. Although NMOSD can present with bilateral optic neuritis, it is not included in the choices here. Serological testing for MOG antibodies is key in confirming MOGAD. Acute management of MOGAD typically involves high-dose intravenous corticosteroids to reduce inflammation. In refractory cases, intravenous immunoglobulin (IVIG) or plasma exchange may be used. During pregnancy and lactation, corticosteroids can be considered with caution; the lowest effective dose should be used to minimize potential risks to the fetus or neonate, and appropriate counseling regarding risks and benefits is important. Option A (MOGAD) is correct because the clinical picture\u2014adolescent patient, bilateral optic neuritis, and isolated optic nerve involvement on MRI\u2014is most consistent with MOGAD. Option B (ADEM) would usually present with multifocal brain lesions and encephalopathy, while Option C (MS) is more often associated with unilateral optic neuritis and additional brain lesions. 1) MOGAD frequently presents with bilateral optic neuritis in children and adolescents. 2) A normal brain MRI (outside the optic nerves) helps differentiate MOGAD from MS and ADEM. Recent guidelines and studies have increasingly recognized MOGAD as a distinct clinical entity. The use of serum anti-MOG antibody testing is now standard in suspected cases, and treatment strategies continue to evolve with ongoing clinical research.",
    "exam_year": "2024",
    "exam_type": "Part II",
    "image_url": "https://drive.google.com/file/d/1l_Ozcxdm4Uv280fV90GRzmEBk3nJBr4h/preview"
  },
  {
    "question": "Patient with optic neuritis symptoms and brain MRI showing multiple white matter lesion periventricular, which of the following is true?",
    "option_a": "30% of patient will progress to multiple sclerosis in 15 years, recommend starting DMT",
    "option_b": "30% of patient will progress to multiple sclerosis in 15 years, recommend not to start DMT",
    "option_c": "50% of patient will progress to multiple sclerosis in 15 years, recommend starting DMT",
    "option_d": "50% of patient will progress to multiple sclerosis in 15 years, recommend not to start DMT",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Optic neuritis, particularly when accompanied by characteristic brain MRI findings (such as multiple periventricular white matter lesions), is a recognized precursor to clinically definite multiple sclerosis (MS). The risk of conversion to MS is significantly influenced by MRI findings that fulfill the dissemination in space criteria. The presence of demyelinating lesions on MRI indicates active inflammatory processes in the central nervous system. In patients presenting with optic neuritis, multiple periventricular lesions represent underlying demyelination, which inherently increases the risk of future clinical episodes and progression to full-blown MS. Studies have shown that patients with optic neuritis and the presence of brain lesions meeting the McDonald criteria have approximately a 50% risk of developing MS over a 15-year period. These lesions are typically periventricular, ovoid, and serve as a marker for disseminated disease. The evaluation of a patient with optic neuritis includes a detailed clinical history, visual symptom assessment, and neuroimaging studies (MRI). Differential diagnoses include isolated optic neuritis due to other causes (e.g., MOGAD) and non-inflammatory optic neuropathies. However, the presence of multiple periventricular lesions strongly suggests a demyelinating process like MS. For patients with a high risk of conversion to MS (approximately 50% over 15 years), early initiation of disease-modifying therapy (DMT) is recommended to reduce the risk of further clinical relapses and accumulation of disability. First-line DMT options include interferon-beta, glatiramer acetate, and newer agents such as dimethyl fumarate and teriflunomide. In the context of pregnancy and lactation, choices must be carefully evaluated: agents like interferon-beta and glatiramer acetate have better-established safety profiles compared to others, and counseling about timing and potential risks is crucial. Option C is correct: studies indicate that in patients with optic neuritis and multiple periventricular lesions, approximately 50% progress to MS over 15 years, and current treatment guidelines advocate for the early initiation of DMT in high-risk individuals. The other options either underestimate the conversion rate or recommend against treatment, which is not supported by current evidence. 1) Abnormal brain MRI in the setting of optic neuritis significantly increases the risk of developing MS. 2) Early intervention with DMT can alter the natural history of MS by reducing relapses and delaying long-term disability. Long-term follow-up studies, such as those derived from the Optic Neuritis Treatment Trial and subsequent research, have consistently reinforced the notion that patients with optic neuritis and abnormal MRI findings have a roughly 50% risk of conversion to MS. Current guidelines advocate for early treatment in high-risk patients, with ongoing research refining the optimal timing and choice of DMT.",
    "exam_year": "2024",
    "exam_type": "Part II",
    "image_url": "https://drive.google.com/file/d/1TWhWO36f-u3ZtCw-kOikHAncSJlNAQUx/preview"
  },
  {
    "question": "24-year-old female developed abrupt vision loss (did not mention painful or painless) in left eye 5 days ago then affected the right eye after two to three days and was static thereafter. Exam showed decreased visual acuity, what to do next?",
    "option_a": "No treatment needed",
    "option_b": "Pulse steroids",
    "option_c": "Plasmapheresis",
    "option_d": "IVIG",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "This patient\u2019s presentation is most consistent with an acute demyelinating optic neuritis, which often presents in young females and can be an initial manifestation of multiple sclerosis. In acute optic neuritis, inflammation of the optic nerve causes a rapid decline in vision. Optic neuritis is primarily due to an immune\u2010mediated inflammatory demyelination of the optic nerve. T\u2010cell mediated responses against myelin antigens lead to demyelination and conduction block within the optic nerve, ultimately impairing the transmission of visual signals. High-dose corticosteroids help reduce inflammation and shorten the recovery time. Most patients present with subacute, monocular visual loss that is frequently accompanied by pain on eye movement. Although classically unilateral, bilateral involvement or sequential involvement of the eyes (as in this case) may be seen especially in more aggressive or neuromyelitis optica spectrum disorders. The decrease in visual acuity on exam aligns with optic nerve inflammation. The diagnosis is usually clinical with supporting tests such as visual evoked potentials and MRI of the brain/orbits. Differential diagnoses include ischemic optic neuropathy (typically in older individuals and often painless), compressive optic neuropathy, and Leber\u2019s hereditary optic neuropathy. MRI may show enhancement of the affected optic nerve. According to current guidelines, the first-line management for acute optic neuritis is high-dose IV corticosteroids (e.g., IV methylprednisolone 1 g daily for 3\u20135 days) to hasten visual recovery. This is typically followed by an oral steroid taper. In pregnancy, corticosteroids are generally considered acceptable when clearly indicated, though risks and benefits must be weighed. Plasmapheresis or IVIG are reserved for patients who do not respond to steroid therapy. Option A (No treatment) is incorrect because untreated optic neuritis can lead to prolonged visual disability. Option B (Pulse steroids) is correct as it is the first-line treatment. Option C (Plasmapheresis) and Option D (IVIG) are generally reserved for steroid-refractory cases. 1. Although IV steroids may speed recovery, long-term visual outcomes are similar regardless of treatment in typical optic neuritis. 2. Optic neuritis is a common presenting sign of MS, and patients should be monitored for further neurological symptoms. 3. Pain on eye movement is a classic symptom. The Optic Neuritis Treatment Trial (ONTT) and subsequent research confirm that high-dose IV corticosteroids shorten the time to visual recovery. Recent guidelines continue to support this approach, and ongoing studies are examining optimal dosing, especially in special populations like pregnant patients.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young patient was found to be unresponsive in bed and sleepy but arousable, taken to emergency room examination found no focal neurologic deficit, MRI brain attached showing bilateral hyperintensity of thalamus and area around the foramen and right insular, what is the most appropriate step?",
    "option_a": "Lumbar puncture",
    "option_b": "AQP Antibodies",
    "option_c": "Anti Mag antibodies",
    "option_d": "Toxicology screen",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "In a young patient with altered mental status and an MRI demonstrating bilateral thalamic and insular hyperintensities, one key consideration is a toxic-metabolic encephalopathy. When the history includes unresponsiveness without focal deficits, a toxic ingestion should be strongly suspected. Various toxins can induce global cerebral dysfunction by disrupting neuronal metabolism. In toxic encephalopathies, the resulting edema and metabolic failure can manifest as symmetric or regionally selective hyperintensities on MRI due to cytotoxic or vasogenic edema in vulnerable areas such as the thalamus and insular cortex. The patient\u2019s sleepy yet arousable state without focal deficits suggests a diffuse process rather than a localized structural lesion. This pattern, combined with the MRI findings, raises concern for a toxic or metabolic cause rather than an inflammatory or vascular etiology. The differential diagnosis includes toxic ingestion, metabolic disturbances (e.g., hypoglycemia, electrolyte imbalances), encephalitis, and less commonly deep cerebral venous thrombosis (which often has additional signs such as headache and focal deficits). Differentiation is achieved via laboratory evaluations including toxicology screening, metabolic panels, lumbar puncture (if infection is suspected), and MR venography if venous thrombosis is a consideration. The initial management consists of promptly identifying the toxin through a comprehensive toxicology screen and supportive care. In parallel, treat any metabolic disturbances, secure the airway if necessary, and provide symptomatic treatment. In cases of confirmed toxic ingestion, specific antidotes may be administered. For pregnant or lactating patients, the selection of detoxification therapies requires careful consideration due to potential fetal effects, though maternal stabilization is prioritized. Option A (Lumbar puncture) is more appropriate when an infectious or inflammatory etiology such as encephalitis is suspected; however, the MRI pattern and history favor a toxic/metabolic cause. Option B (AQP antibodies) is used for diagnosing neuromyelitis optica and is irrelevant here. Option C (Anti-MAG antibodies) is associated with demyelinating neuropathies rather than central toxic encephalopathies. Option D (Toxicology screen) is correct as it is the most appropriate next step to evaluate for toxin ingestion. 1. Always consider a toxic/metabolic etiology in younger patients with altered mental status and non-focal neurological exams. 2. Bilateral thalamic involvement on MRI is a red flag that can be seen in several metabolic and toxic states. 3. A thorough toxicology screen can be life-saving in undifferentiated encephalopathy. Recent studies emphasize the importance of early identification of toxins in encephalopathic patients to guide targeted therapy and improve outcomes. Current emergency protocols support obtaining a toxicology screen as part of the initial workup in unexplained altered mental statuses.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Same question Elderly patient with confusion, seizure and weakness, brought to emergency, MRI brain attached showed picture of multiple microhemorrhages, what is the treatment?",
    "option_a": "IV methylprednisolone",
    "option_b": "IVIG",
    "option_c": "Plasmapheresis",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "In an elderly patient presenting with confusion, seizures, and weakness, the presence of multiple microhemorrhages on MRI is strongly suggestive of an inflammatory vasculopathy related to cerebral amyloid angiopathy (CAA) \u2013 specifically the inflammatory variant known as CAA-related inflammation (CAA-ri) or amyloid beta\u2013related angiitis. CAA-ri is an immune-mediated inflammatory response directed against amyloid-beta deposits in cerebral vessels. The inflammatory reaction leads to vessel wall damage, resulting in microhemorrhages and vasogenic edema, which manifest on MRI. This differs from classic CAA, where bleeding is due to vessel fragility without an inflammatory component. Clinically, CAA-ri often presents with an acute or subacute onset of cognitive decline, focal neurological deficits, seizures, and headache. The elderly are predominantly affected. The imaging finding of multiple microhemorrhages in a patient with these symptoms supports an inflammatory process superimposed on CAA. The differential includes primary central nervous system vasculitis, hypertensive microangiopathy, and non-inflammatory CAA. Distinguishing features include the pattern of MRI changes (microhemorrhages often with associated T2 hyperintensities in inflammatory variants), clinical course, and laboratory findings. Brain biopsy is definitive but is reserved for atypical cases. The first-line treatment for CAA-ri is high-dose IV corticosteroids (e.g., IV methylprednisolone), which help suppress the inflammatory response. In refractory cases, additional immunosuppressive therapies, such as cyclophosphamide, may be considered. For pregnant or lactating patients\u2014while CAA-ri is rare in this population\u2014the risks and benefits of high-dose steroids must be carefully weighed; however, maternal stabilization remains the priority and steroids are often used if indicated. Option A (IV methylprednisolone) is correct as it addresses the inflammatory component of CAA-ri. Option B (IVIG) and Option C (Plasmapheresis) are not standard treatments for this condition. The absence of a clearly defined Option D further supports that steroids remain the central treatment choice. 1. CAA-ri is the inflammatory subset of CAA that is responsive to corticosteroids and should be distinguished from non-inflammatory CAA. 2. Early recognition and treatment with steroids are critical to improving neurological outcomes in CAA-ri. 3. Seizures in elderly patients with microhemorrhages warrant evaluation for inflammatory vasculopathies. Recent clinical studies and guidelines underscore the responsiveness of CAA-ri to high-dose corticosteroids, with many case series supporting prompt steroid use to reduce inflammation and prevent further neurological decline.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient known case of multiple sclerosis has double vision, exam showed left impaired adduction and right abduction nystagmus, where is the localization?",
    "option_a": "Left MLF",
    "option_b": "Right MLF",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The patient with multiple sclerosis presenting with diplopia and the described ocular findings is exhibiting a classic internuclear ophthalmoplegia (INO). INO is characterized by an impaired adduction in the affected eye and nystagmus in the contralateral abducting eye. INO results from a lesion in the medial longitudinal fasciculus (MLF), a neural tract that coordinates horizontal eye movements by connecting the abducens nucleus of one side to the contralateral oculomotor nucleus. In multiple sclerosis, demyelination frequently involves the MLF, disrupting this coordination and leading to the characteristic presentation. In this case, when the patient attempts lateral gaze to the left, the left eye fails to adduct properly while the right eye demonstrates abduction nystagmus. This mismatch is pathognomonic for a left INO, indicating a lesion in the left MLF. INO is one of the most common ocular motor deficits in MS. Diagnosis is largely clinical with confirmation from the patient\u2019s history of MS. Differential diagnoses for diplopia include internuclear ophthalmoplegia from brainstem stroke, myasthenia gravis (which typically shows fatigable weakness without isolated adduction impairment), and other brainstem pathologies. Neuroimaging (preferably MRI) can help localize the lesion and exclude alternative causes. Management focuses on treating the underlying demyelinating process. In acute MS exacerbations that manifest with brainstem involvement, high-dose IV corticosteroids are typically administered. Symptomatic treatments for diplopia, including prism glasses or eye patching, may also be considered. For pregnant or lactating patients with MS exacerbations, steroids remain the first-line treatment, and the risk\u2013benefit ratio should be carefully evaluated. Option A (Left MLF) is correct because the clinical findings (left impaired adduction with contralateral abduction nystagmus) localize the lesion to the left medial longitudinal fasciculus. Option B (Right MLF) is incorrect as it would produce the opposite pattern of eye movement abnormalities. Options C and D are not provided but are irrelevant based on the clinical findings. 1. INO is highly characteristic of multiple sclerosis in younger patients and of stroke in older patients. 2. The lesion in INO is in the MLF, leading to dissociated horizontal gaze abnormalities. 3. A careful ocular motor examination is essential to localize brainstem lesions. Current research in MS continues to emphasize the role of demyelination in brainstem pathways, including the MLF. Recent guidelines advocate for prompt steroid therapy during acute exacerbations with brainstem involvement, and advanced neuroimaging techniques help in accurately localizing lesions.",
    "exam_year": "2024",
    "exam_type": "Part II"
  }
]